STEMI Clinical Trial
Official title:
CMR or Angiography for FFR-guided Revascularisation in ST-elevation Myocardial Infarction
Around 50% of patients that present with ST Elevation Myocardial Infarction (STEMI) have residual disease in the non-culprit lesions. If the residual disease should be treated, what should guide intervention? Fractional Flow Reserve (FFR) has been proposed as a guide for intervention, however new developments in cardiovascular magnetic resonance (CMR) allows for non-invasive FFR measurements. If FFR from CMR can predict physiological significant stenosis as good as FFR from invasive angiography, unnecessary invasive producers can be avoided in patients with STEMI.
Early reperfusion of epicardial coronaries is essential for salvage of ischemic myocardium, reducing both morbidity and mortality in patients with ST elevation myocardial infarction (STEMI). Current European Society of Cardiology guidelines recommend percutaneous coronary intervention (PCI) of the infarct related artery (IRA) for patients presenting with STEMI, with residual disease initially being treated conservatively. Large meta-analyses of observational studies have shown that PCI of the IRA only results in a reduced mortality compared to full revascularization in patients with STEMI and simultaneous multivessel disease. However, recent small randomized controlled trials indicate that full revascularization reduces morbidity, but have been underpowered to show any reduction in mortality. Furthermore, physiological guidance of coronary intervention by fractional flow reserve (FFR) reduces mortality compared to angiography guided PCI in both stable angina and non-STEMI (NSTEMI). However, if performing full revascularization guided by FFR in patients with STEMI improves clinical outcome, compared to initial conservative approach is not known. Assessment of myocardial perfusion in rest and during pharmacological stress is widely used for non-invasive diagnosis of myocardial ischemia, where cardiovascular magnetic resonance (CMR) has a high diagnostic accuracy. Newly developed first pass perfusion imaging with cardiovascular magnetic resonance (CMR) allows for quantification of myocardial perfusion, and CMR derived FFR. However, it is currently not known if FFR from CMR and invasive angiography correlate with each other. If FFR from CMR can predict physiological significant stenosis as good as FFR from invasive angiography, unnecessary invasive producers can be avoided in patients with STEMI. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT02871622 -
BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM
|
N/A | |
Completed |
NCT01452139 -
Pharmacogenetic Approach to Anti-platelet Therapy for the Treatment of ST-segment Elevation Myocardial Infarction (STEMI)
|
Phase 2/Phase 3 | |
Completed |
NCT01325116 -
Delayed Educational Reminders in Acute Myocardial Infarction (MI)
|
N/A | |
Completed |
NCT01625104 -
Randomized Trial of a Quality Improvement Intervention to Decrease D2B Time in Primary PCI for AMI
|
N/A | |
Completed |
NCT04023266 -
A Pilot Randomized Controlled Trial of Intravenous N-acetyl Cysteine in STEMI
|
Phase 2 | |
Completed |
NCT02170103 -
Microvascular Recovery With Ultrasound in Myocardial Infarction (MRUSMI) Post PCI Trial
|
N/A | |
Completed |
NCT03103620 -
Safety and Effectiveness Evaluation of COBRA PzF Coronary Stent System: A Post Marketing Observational Registry
|
||
Not yet recruiting |
NCT05975567 -
Deploying Novel Imaging Modalities Towards a Three-dimensional (3D) CARDIOvascular PATHology
|
||
Enrolling by invitation |
NCT03328156 -
Erectile Dysfunction After Percutaneous Coronary Intervention Versus the Thrombolytic Therapy in Acute ST Elevation Myocardial Infarction
|
N/A | |
Completed |
NCT04017169 -
No Reflow Phenomenon Incidence and Predictors
|
||
Completed |
NCT03470441 -
A Study of Acute Myocardial Infarction Using FDY-5301
|
Phase 2 | |
Active, not recruiting |
NCT01433627 -
Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX
|
Phase 3 | |
Completed |
NCT01197742 -
Sweetheart-Register: Risk Management of Diabetics With Acute Myocardial Infarction
|
N/A | |
Terminated |
NCT03439150 -
Resistance STEMI Study
|
N/A | |
Recruiting |
NCT03998319 -
A Study of Low-dose Intracoronary Thrombolytic Therapy in STEMI (Heart Attack) Patients.
|
Phase 3 | |
Not yet recruiting |
NCT05974930 -
Intravascular ULTRAsound-Guided PCI in Patients With ST-Elevation Myocardial Infarction
|
||
Active, not recruiting |
NCT03102723 -
Platelet Inhibition to Target Reperfusion Injury
|
Phase 2 | |
Completed |
NCT03930589 -
Remote Ischemic Conditioning in STEMI to Decrease Infarct Size
|
N/A | |
Not yet recruiting |
NCT04912167 -
The Effects of Sacubitril-Valsartan vs Enalapril on Left Ventricular Remodeling in ST-elevation Myocardial Infarction
|
Phase 3 | |
Completed |
NCT02942550 -
Methylnaltrexone as a Method to Improve Ticagrelor Uptake in Morphine Treated STEMI Patients
|
Phase 4 |